A further two patients were treated 3rd May in SpectraCure's clinical trial for treatment of recurrent prostate cancer at the Princess Margaret Cancer Centre in Toronto. The treatments were done with the method based on photodynamic therapy (PDT) developed by SpectraCure. As before, the treatments were performed by a team led by Drs Neil Fleshner and Nathan Perlis and everything passed well, the company's technology worked well according to plans and patients are doing well.
"It is very pleasing that we have been able to treat two patients in one day. This is an important step in order to be able to keep a higher rate in the clinical program in the near future at the hospitals involved", commenting CEO Masoud Khayyami.
At the treatments, Dr Caroline Moore from University College London (UCL) attended as an observer. Dr Moore is the principal investigator of the part of the clinical trial that will be conducted at University College London Hospital.
"It was very helpful to observe the new procedures," Dr Moore said after attending the treatments in Toronto. “We now look forward to starting the study at UCLH.”
The treatment method, PDT, means that the patient is given a light-activated drug that accumulates in the tumour. When the cancer tissue is illuminated using the SpectraCure light delivery system, the drug is activated and the tumour is eliminated.
The target group of the study is patients with recurrent prostate cancer after radiotherapy. For this patient group, routine curative treatment options are lacking and they are normally given hormone therapy to inhibit tumour growth. Hormonal treatment often causes undesirable side effects. SpectraCure aims to offer a curative treatment option for these patients, with fewer and less severe side effects.
